Non-Small Cell Lung Cancer- Localized and Unresectable

Correlatives

No Trials Currently Available

Inoperable Stage I/II

IRB#10077
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

IRB#19566
A Phase II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA1/2 MUTATION STAGE IV OR RECURRENT NSCLC (LUNG-MAP SUB-STUDY)

Inoperable Stage IIIA/B

IRB#20077
A Phase II Randomized Study of Ramucirumab plus MK3475 (Pembrolizumab) versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

IRB#19566
A PHASE II STUDY OF RUCAPARIB IN PATIENTS WITH GENOMIC LOH HIGH AND/OR DELETERIOUS BRCA1/2 MUTATION STAGE IV OR RECURRENT NSCLC (LUNG-MAP SUB-STUDY)

CROSS-DISEASE TRIALS:

IRB# 19992 EAY131 (MATCH)
IRB# TBD S1609 (DART)

Please contact Matt Crocker at crockerm@ohsu.edu or 503-418-9389 with questions.

http://www.ohsu.edu/research/rda/so/knight.php